Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05983744 · ClinicalTrials.gov registry record · NA
Pulsatile Perfusion Therapy Phase II
A NA study of Hemorrhage, sponsored by Caroline Rickards.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT05983744: Completed NA study of Hemorrhage, sponsored by Caroline Rickards.
NCT05983744 is a NA study of Hemorrhage that has completed, run by Caroline Rickards. The registered enrollment target is 21 participants, below the 266-participant average among 20 other Hemorrhage trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05983744, a NA study of Hemorrhage, has completed, sponsored by Caroline Rickards.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Individuals who suffer from a stroke, cardiac arrest, or traumatic bleeding (hemorrhage) injuries often have compromised blood flow and oxygen to the brain which can lead to the death of brain cells, and if the patient survives, subsequent difficulty in thinking and performing tasks of daily living. Traditionally, delivery of a constant flow of blood to the brain has been thought to be the most important factor for the survival of brain cells. In this study, a novel intervention will be assessed called "pulsatile perfusion therapy", delivering blood flow in a slow pulsing pattern. It is anticipated this intervention will improve brain blood flow and oxygenation during these serious clinical events. There is a specific interest in whether delivery of brain blood flow with a slow pulsatile pattern will improve oxygenation of brain tissue, particularly when the brain is challenged under low oxygen (hypoxia) and low volume (hypovolemia) conditions, simulating stroke, cardiac arrest, and hemorrhage. A technique called oscillatory lower body negative pressure (OLBNP) will be used in healthy human participants, facilitating delivery of blood flow to the brain with different pulsing patterns. This technique will allow for determination of the ideal pattern of brain blood flow that improves oxygenation of the brain tissue. Measurements will be made of substances in the blood that may be released with pulsatile flow which act on the blood vessels to increase flow and delivery of oxygen.
Primary Outcome
Cerebral tissue oxygen saturation
Conditions Studied
Interventions
- OTHER 0 Hz Control
- OTHER 0.1 Hz PPT
- OTHER 0.05 Hz PPT
Study Locations (1)
Texas
- University of North Texas Health Science Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-02-27 |
| Est. Completion | 2021-12-17 |
| Phase | NA |
What the finished NCT05983744 record still lists
NCT05983744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 266-participant average among 20 other Hemorrhage trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Hemorrhage appearing as the primary indexed condition, and to 3 interventions - of which 0 Hz Control is the first listed.
NCT05983744 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05983744 about?
NCT05983744 is a clinical study titled "Pulsatile Perfusion Therapy Phase II". Individuals who suffer from a stroke, cardiac arrest, or traumatic bleeding (hemorrhage) injuries often have compromised blood flow and oxygen to the brain which can lead to the death of brain cells, and if the patient survives, subsequent difficulty in thinking and performing tasks of daily living....
What is the current status of trial NCT05983744?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2020-02-27. Estimated completion is 2021-12-17.
What conditions does trial NCT05983744 study?
This clinical trial studies the following conditions: Hemorrhage.
What interventions are being tested in trial NCT05983744?
The interventions under investigation include: 0 Hz Control (OTHER), 0.1 Hz PPT (OTHER), 0.05 Hz PPT (OTHER).
Who is sponsoring clinical trial NCT05983744?
This trial is sponsored by Caroline Rickards, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05983744 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05983744's enrollment target sits among peer trials
21 21st of 20 the lowest of 20 other Hemorrhage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Onyx™ Liquid Embolic IDE Clinical Study
RECRUITING · NA
-
Q Therapeutic System for Chronic Stroke Recovery
RECRUITING · NA
-
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
RECRUITING · Phase 2
-
Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation
RECRUITING · Phase 2
-
NIRS Monitoring in Premature Infants
RECRUITING
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI